Engineered t cells take aim at prostate cancer in early trial

This early-phase study tests whether a patient's own immune cells (T cells) can be genetically modified to better recognize and attack prostate cancer cells. The main goal is to check the safety of different doses in men with advanced prostate cancer that no longer responds to hormone therapy. The approach involves removing T cells from the blood, adding a new gene to help them target a protein called PSMA on cancer cells, and infusing them back into the patient.